Latest news from Magnus Medical on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/magnus-medical-receives-fda-clearance-for-the-saint-neuromodulation-system-for-non-invasive-individualized-and-precise-treatment-of-severe-depression/?sc=rsin /articles/magnus-medical-receives-fda-clearance-for-the-saint-neuromodulation-system-for-non-invasive-individualized-and-precise-treatment-of-severe-depression/?sc=rsin Tue, 06 Sep 2022 10:05:17 EST Magnus Medical received clearance from the U.S. FDA for the SAINT(tm) Neuromodulation System for the treatment of major depressive disorder in adults who have failed to achieve satisfactory improvement from prior antidepressant medications. Magnus Medical /articles/magnus-medical-launches-with-breakthrough-device-designation-for-rapid-individualized-treatment-of-major-depression-and-25m-in-series-a-financing/?sc=rsin /articles/magnus-medical-launches-with-breakthrough-device-designation-for-rapid-individualized-treatment-of-major-depression-and-25m-in-series-a-financing/?sc=rsin Fri, 29 Oct 2021 06:05:08 EST Magnus Medical, Inc., a medical device company, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its individualized, rapid-acting, non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments. Magnus Medical